Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-labeled PD-L1 PET Tracer is a radiopharmaceutical diagnostic agent currently in preclinical development by TRIMT. It consists of a ligand labeled with the positron-emitting radioisotope Gallium-68 (68Ga) that specifically targets Programmed cell Death Ligand 1 (PD-L1). The tracer is designed for use with positron emission tomography (PET) imaging to non-invasively visualize and quantify PD-L1 expression levels within the tumor microenvironment. By providing a whole-body map of PD-L1 expression, this imaging agent aims to improve the selection and stratification of patients for immunotherapy, particularly those being considered for checkpoint inhibitors targeting the PD-1/PD-L1 pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-labeled PD-L1 PET Tracer.